Antiretroviral (ARV) therapy in HIV patients can cause hyperlipidaemia, glucose intolerance and insulin resistance, which increase the risk of cardiovascular disease (CVD). An audit carried out in Manchester found that CVD risk factors were common among HIV patients receiving ARVs; however, the management of risk factors was not satisfactory. Adopting a formal system to identify and manage CVD risk factors as well as appropriate referral for specialist management of complications of ARV therapy would improve patient care.
Friis-MollerN, WeberR, ReissP, Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS2003;17:1179–93
2.
Friis-MollerN, SabinCA, WeberR, Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med2003;349:1993–2003
3.
JBS 2. Joint British Societies' guidelines on prevention of Cardiovascular Disease in clinical practice. Heart2005;91(Suppl 5):v1–52
4.
World Health Organisation. Cardiovascular Disease, Guidelines for Assessment and Management of Cardiovascular Risk. http://www.who.int/cardiovascular_diseases/guidelines/Full%20text.pdf. 2007
5.
National Cholesterol Education Program (NCEP). Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf. 2001
